Mesoblast MESO 深 滬
等待開盤 08-01 09:30:00 美东时间
14.17
-0.380
-2.61%
華盛通- 最 高14.53
- 今 開14.50
- 成交量 15.94万股
- 最 低 14.045
- 昨 收 14.55
- 總市值 18.38亿
- 52周最高 21.50
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 12.66
- 委 比 19.15%
- 總股本 1.30亿
- 歷史最高 58.4372
- 量 比 0.69
- 振 幅 3.33%
- 歷史最低 1.9406
- 每 手 1
- 風險率 1.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Mesoblast Limited reported strong performance in Q4 FY2026, with Ryoncil® generating $36 million in net revenue and $115 million for the full year post-FDA approval. The company is expanding Ryoncil's indications to adults with steroid-refractory acute GvHD and other severe inflammatory diseases. Rexlemestrocel-L met its target of 300 patients in a pivotal Phase 3 trial for chronic low back pain. Mesoblast also unveiled next-generation MSC strate...
07-30 00:57
State Street Exits Substantial Holding in Mesoblast
An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblas...
07-24 15:17
Mesoblast Cancels Over 1.2 Million Lapsed Options
Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast Limited h...
07-14 15:47
Mesoblast Issues 8.2 Million Unquoted Employee Options
An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblas...
07-14 15:31
Mesoblast posts US$115m first-year Ryoncil revenue and strengthens capital position
Mesoblast Limited ( ($AU:MSB) ) has shared an announcement. Mesoblast reported ...
07-10 08:07
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Mesoblast Limited reported net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026, driven by strong uptake of Ryoncil®. CEO Dr. Silviu Itescu expressed satisfaction with revenue exceeding initial projections and anticipates continued growth in the next fiscal year. Ryoncil®, the first FDA-approved mesenchymal stromal cell (MSC) product, is the only treatment for steroid-refractory acute graft-versus-...
07-10 00:30
8 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
07-07 01:35
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
06-30 01:35
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
Issued on behalf of Conexeu Sciences Inc. Companies mentioned: Conexeu Sciences Inc. (NASDAQ: CNXU), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Evolus, Inc. (NASDAQ: EOLS), Bi...
05-22 22:31
Alpha Buying: Insider Conviction in High-Risk Biotech
Insider buying matters in every industry, but it carries a special weight in bi...
05-08 00:04
